Fluidx Medical have released details on the clinical use of their GPX embolic device, demonstrating its ability to block flow to small microvasculature and large tumour feeding vessels.
“The versatility of the GPX product has been demonstrated in a variety of interventional oncology uses,” says Andrew Holden, director of Interventional Radiology, Auckland City Hospital, Auckland, New Zealand. “We have seen excellent distal penetration and backfilling of larger vessels in our tumour cases.”
According to Fluidx Medical, the GPX embolic device is an embolic designed “to combine the benefits of other embolics like coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions”. GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material upon delivery without polymerisation or dimethyl-sulfoxide (DMSO) precipitation.
“We saw excellent filling of the distal branches and complete tumour devascularisation,” says Martin Krauss, head of Interventional Radiology, Christchurch Hospital, Christchurch, New Zealand. “The patient exhibited marked decrease in haematuria following the procedure. Since we were not worried about catheter entrapment, we could take our time and ensure that we occluded all the feeding vessels of the tumour.”
GPX is packaged ready-to-use in a syringe, requires less than one minute of tableside preparation by the clinician, and may be delivered through standard catheters or microcatheters, according to Fluidx Medical Technology data on file. Clinicians can decide at time of care to use GPX alone or as a complement to coils or other embolic technologies.
In a recent case at Christchurch Hospital, the GPX embolic device was delivered through long, thin microcatheters, including the 2Fr Terumo Progreat Alpha 130cm length microcatheter with an inner diameter of 0.019 inches (0.48mm).
The GPX embolic device is under development and does not have marketing clearance or approval in any market at this time. It is for investigational use (in New Zealand) only.